Labcorp Holdings Inc. (NYSE:LH) Shareholders to Get $0.72 Quarterly Dividend

Labcorp Holdings Inc. (NYSE:LH) announced a quarterly dividend on Tuesday, October 20th. Stockholders of record on Tuesday, November 24th will be given a dividend of $0.72 per share by the medical research company on Friday, December 11th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Tuesday, November 24th.

Labcorp has a payout ratio of 16.4% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Labcorp to earn $19.69 per share next year, which means the company should continue to be able to cover its $2.88 annual dividend with an expected future payout ratio of 14.6%.

Labcorp Trading Up 1.6%

NYSE LH opened at $328.87 on Thursday. The company’s 50 day moving average price is $320.56 and its 200 day moving average price is $290.33. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.53 and a current ratio of 1.80. Labcorp has a one year low of $244.52 and a one year high of $341.80. The firm has a market capitalization of $26.67 billion, a price-to-earnings ratio of 27.38, a PEG ratio of 1.84 and a beta of 0.87.

Labcorp (NYSE:LH) last released its earnings results on Thursday, July 30th. The medical research company reported $4.99 EPS for the quarter, beating the consensus estimate of $4.78 by $0.21. Labcorp had a return on equity of 16.74% and a net margin of 6.99%. The company had revenue of $3.73 billion during the quarter, compared to analysts’ expectations of $3.71 billion. During the same period in the prior year, the business posted $4.35 EPS. The business’s revenue was up 5.8% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. On average, sell-side analysts predict that Labcorp will post 18.32 EPS for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on LH shares. Weiss Ratings raised shares of Labcorp from a “buy (b+)” rating to a “buy (a-)” rating in a research note on Wednesday. Morgan Stanley lifted their target price on Labcorp from $308.00 to $338.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. Piper Sandler raised their price target on shares of Labcorp from $300.00 to $309.00 and gave the stock a “neutral” rating in a report on Tuesday, August 4th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $306.00 target price on shares of Labcorp in a research report on Friday, July 31st. Finally, JPMorgan Chase & Co. increased their price objective on Labcorp from $330.00 to $360.00 and gave the stock an “overweight” rating in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, Labcorp presently has a consensus rating of “Moderate Buy” and an average price target of $337.73.

Labcorp Company Profile

Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences and healthcare company headquartered in Burlington, North Carolina. The company provides laboratory testing and diagnostic services to physicians, hospitals, health systems, employers, insurers and consumers.

Through its diagnostics operations, Labcorp offers routine and specialty testing, oncology diagnostics, women’s health testing, genetic testing, pathology services and other laboratory services.